Information Provided By: 
Fly News Breaks for November 12, 2018
TSRO
Nov 12, 2018 | 07:57 EDT
Jefferies analyst Eun Yang lowered her price target for Tesaro to $25 saying the company's new immune-oncology data is "underwhelming." With slowing Zejula sales growth, Tesaro has been increasingly focused on I/O programs, Yang tells investors in a research note. She believes the company's data for new I/O therapy "fails to show meaningful additive effects when combined with its anti-PD-1." The analyst keeps a Hold rating on Tesaro.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
